Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen

Breast Cancer Research and Treatment

Volumn 125, Issue 2, 2011, Pages 505-510

  Siegelmann Danieli, Nava ^a   Kurnik, Daniel ^a,b   Lomnicky, Yossi ^a   Vesterman Landes, Janet ^a   Katzir, Itzhak ^a   Bialik, Martin ^a   Loebstein, Ronen ^a,b  

^a MACCABI HEALTHCARE SERVICES   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

CYP2D6 inhibition; Disease free survival; Drug interaction; Overall survival; Tamoxifen

Indexed keywords

AMIODARONE; CHLORPHENIRAMINE; CIMETIDINE; CLOMIPRAMINE; CYTOCHROME P450 2D6; ESTROGEN RECEPTOR; FLUOXETINE; HALOPERIDOL; PAROXETINE; QUINIDINE; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RELAPSE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT DURATION; TUMOR CLASSIFICATION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYTOCHROME P-450 CYP2D6; DISEASE-FREE SURVIVAL; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TAMOXIFEN; TREATMENT OUTCOME;

EID: 78650996411     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1008-7     Document Type: Article

References (26)

1. S Borges Z Desta Z Li, et al. 2006 Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment Clin Pharamacol Ther 80 1 64 74
2. X Wu JR Howse M Subramaniam MP Goetz JN Ingle TC Spelbsberg 2009 The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor α for degradation in breast cancer cells Cancer Res 69 5 1722 1727 1:CAS:528:DC%2BD1MXisFSrtr8%3D 10.1158/0008-5472.CAN-08-3933 19244106
3. K Kiyotani T Mushiroda M Sasa, et al. 2008 Impact of CYP2D6 10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy Cancer Sci 99 5 995 999 1:CAS:528:DC%2BD1cXlslCrtrc%3D 10.1111/j.1349-7006.2008.00780.x 18294285 (Pubitemid 351997603)
4. W Schroth MP Goetz U Hamann, et al. 2009 Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with Tamoxifen J Am Med Assoc 302 13 1429 1436 1:CAS:528:DC%2BD1MXht1CksrjO 10.1001/jama.2009.1420
5. SA Scott L Edelmann R Kornreich M Erazo R Desnick 2007 CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population Pharmacogenomics 8 7 721 730 1:CAS:528:DC%2BD2sXnvVersLg%3D 10.2217/14622416.8. 7.721 18240905 (Pubitemid 47288973)
6. W Schroth L Antoniadou P Fritz, et al. 2007 Breast cancer treatment outcome with adjuvant Tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes J Clin Oncol 25 33 5187 5193 1:CAS:528:DC%2BD2sXhsVKnsbzN 10.1200/JCO.2007.12. 2705 18024866 (Pubitemid 350232249)
7. B Bonnani D Macis P Maisonneuve, et al. 2006 Polymorphism in the CYP2D6 metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen trial J Clin Onc 24 22 3708 3709 10.1200/JCO.2006.06.8072 (Pubitemid 46630548)
8. MP Goetz SK Knox VJ Suman, et al. 2007 The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant Tamoxifen Breast Cancer Res Treat 101 1 113 121 1:CAS:528:DC%2BD2sXisVylsg%3D%3D 10.1007/s10549-006-9428-0 17115111 (Pubitemid 47555336)
9. HS Lim H Ju Lee K Seok Lee, et al. 2007 Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer J Clin Oncol 25 25 3837 3845 1:CAS:528:DC%2BD2sXhtFanu7zK 10.1200/JCO.2007.11. 4850 17761971 (Pubitemid 47477258)
10. SA Nowell J Ahn JM Rae, et al. 2005 Association of genetic variation in tamoxifen metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients Breast Cancer Res Treat 91 3 249 258 1:CAS:528:DC%2BD2MXltFGqsLs%3D 10.1007/s10549-004-7751-x 15952058 (Pubitemid 40903087)
11. P Wegman S Elingarami J Carstensen O Stal B Nordenskjold S Wingren 2007 Genetic variants of the CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Breast Cancer Res 91 1 R7 10.1186/bcr1640 (Pubitemid 350215154)
12. Rae JM, Thibert J, Sikora MJ et al (2009) Lack of correlation between genetic polymorphism in tamoxifen metabolizing enzymes with primary endpoints in the IMPACT trial. Cancer Res 69(Suppl):24 (Abstract 2011)
13. Ahern TP, Pedersen L, Cronin-Fenton DP, Sorensen HT, Lash TL (2009) No increase in breast cancer recurrence with concurrent use of Tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarker Prev 18(9):2562-2564
14. Aubert RE, Stanek J, Yao J et al (2009) Risk of breast cancer recurrence in women initiating Tamoxifen with CYP2D6 inhibitors. J Clin Oncol 28(188):CRA508
15. Dezentje V, Van Blijderveen NJ, Gelderblom H et al (2009) Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: a pharmacoepidemiologic study. J Clin Oncol 28(188):CRA509
16. CM Kelly DN Juurlink T Gomes M Duong-Hua KI Pritchard PC Austin LF Paszat 2010 Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study Br Med J 340 c693 10.1136/bmj.c693
17. HK Crewe MS Lennard GT Tucker FR Woods RE Haddock 1992 The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D5 (CYP2D6) activity in human liver microsomes Br J Clin Pharmacol 34 3 262 265 1:CAS:528: DyaK38Xmt1GktLs%3D 1389951
18. P450 Drug Interaction Table. Division of Clinical Pharmacology. School of Medicine, Indiana University. Available at http://medicine.iupui.edu/clinpharm/ ddis/table.asp. Accessed June 16, 2010
19. Early Breast Cancer Trialists Collaborative Group (EBCTCG) 9472 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomized trials Lancet 365 9472 1687 1717
20. TL Lash L Pedersen D Cronin-Fenton TP Ahern CL Rosenberg KL Lunetta RA Silliman S Hamilton-Dutoit JP Garne M Ewertz HT Sorensen 2008 Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram Br J Cancer 99 616 621 1:CAS:528:DC%2BD1cXpslWrsbs%3D 10.1038/sj.bjc.6604533 18665165
21. TL Lash D Cronin-Fenton TP Ahern CL Rosenberg KL Lunetta RA Silliman S Hamilton-Dutoit JP Garne M Ewertz HT Sorensen L Pedersen 2010 Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen Acta Oncol 49 305 312 1:CAS:528:DC%2BC3cXkvVagu7k%3D 10.3109/02841860903575273 20156115
22. TL Lash EA Lien HT Sorensen S Hamilton-Dutoit 2009 Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 10 825 833 1:CAS:528:DC%2BD1MXptlals7s%3D 10.1016/S1470-2045(09)70030-0 19647203
23. L Shi B Dong Z Li, et al. 2009 Expression of ER-α36, a novel variant of estrogen receptor α and resistance to Tamoxifen treatment in breast cancer J Clin Oncol 27 21 3423 3429 1:CAS:528:DC%2BD1MXhtVSqtLvK 10.1200/JCO.2008.17.2254 19487384
24. Hawse JR, Wu X, Subramaniam M et al (2009) The impact of estrogen receptor-beta on the actions of endoxifen in breast cancer cells. Cancer Res 69(Suppl):24 (Abstract 405)
25. RC Coombes E Hall LJ Gibson, et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Eng J Med 350 11 1081 1092 1:CAS:528: DC%2BD2cXitV2qtbc%3D 10.1056/NEJMoa040331 (Pubitemid 38298988)
26. Goetz MP, Berry DA, Klein TE et al (2009) Adjuvant tamoxifen treatment outcome according to cytochrome P450 2D6 (CYP2D6) phenotype in early stage breast cancer: findings from the International Tamoxifen Pharmacogenomics Consortium. Cancer Res 69(Suppl):24 (Abstract 33)